

monitoring antiviral effects because the transcription of these two antigens are regulated by alternative enhancer-promoter systems in the HBV genome.³ Therefore, we analyzed both of these antigens to elucidate their ability to predict relapse of hepatitis after discontinuation of NAs.

Multivariate analysis demonstrated that levels of HBsAg and HBcrAg at the time of NA discontinuation were independent factors significantly associated with relapse of hepatitis. Thus, we believe these factors can also be applied for predicting relapse in patients whose HBV DNA is lower than 3.0 log copies/mL and whose HBeAg is negative at NA discontinuation. HBV DNA levels were further analyzed using a highly sensitive assay based on real-time polymerase chain reaction (PCR). However, even the level of a negative signal did not ensure successful discontinuation of NAs. The results obtained here indicate that the combined use of HBV-related antigens are useful makers for monitoring the effect of anti-viral treatment in ways different from HBV DNA. Finally, since prolonged NA administration was also a significant factor associated with safe discontinuation, physicians are advised to continue patient treatment for at least 16 months for the best possible outcome.

From our data, a tentative model for predicting relapse of hepatitis after discontinuation of NAs was constructed using levels of HBsAg and HBcrAg at discontinuation. A negative result for HBeAg and HBV DNA lower than 3.0 log copies/mL at the time of NA discontinuation are the essential conditions in this system. Levels of HBsAg and HBcrAg were each converted into scores from 0 to 2 partly because two cut-off values were needed for each antigen and partly because a scoring system may be more convenient for clinical use. The sum of the two scores, which ranged from 0 to 4, was used to prospect relapse. We found that group 1 patients who had a low score (0) could be recommended to discontinue NAs because nearly 90% of this group achieved successful discontinuation. Further analysis of factors associated with relapse are needed for group 2 patients who had middle range scores (1 or 2), since the odds of achieving successful discontinuation were approximately 50%. Continuation of NA treatment is recommended for group 3 patients having high scores (3 or 4) because nearly 90% of this group relapsed. However, this recommendation may be reconsidered in patients younger than 40 years; such cases tended to have a lower relapse rate in group 3. It is also noteworthy that relapse occurred mainly during the first and second years following NA discontinuation in

all groups, similarly to a report by Liu *et al.*¹⁴ Thus, clinicians should be vigilant in the early phase after discontinuation.

This study has several limitations. The patients who discontinued NAs were recruited retrospectively, and thus the decision to halt NA treatment was made by individual physicians without uniformly established criteria. Based on this, prospective studies are required to confirm our results. Furthermore, as over 90% of the patients we enrolled had genotype C and over 90% of cases were treated with LVD until discontinuation, the results obtained here can not be applied directly to other HBV genotypes or other types of NAs.

In conclusion, the present study showed that maximal levels of serum ALT and HBV DNA were useful for defining relapse patients after discontinuation of NAs. Along with serum HBV DNA of less than 3.0 log copies/mL and negative serum HBeAg, serum levels of HBsAg and HBcrAg at the time of NA discontinuation were able to predict relapse of hepatitis B and should therefore be considered when establishing uniform guidelines regarding the safe withdrawal of NA treatment. To this end, NA administration of more than 16 months is advisable to achieve successful discontinuation.

ACKNOWLEDGMENTS

THIS RESEARCH WAS supported in part by a research grant from the Ministry of Health, Labor and Welfare of Japan.

We thank Ms. Hiroe Banno for her secretarial assistance and thank Ms. Nozomi Kamijo and Ms. Etsuko Iigahama for their technical assistance. We also thank Mr Trevor Ralph for his English editorial assistance.

REFERENCES

- 1 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. *Hepatology* 2007; 45: 1056–75.
- 2 Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45: 507–39.
- 3 Lee WM. Hepatitis B virus infection. *N Engl J Med* 1997; 337: 1733–45.
- 4 Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. *Gastroenterology* 2007; 132: 1574–85.
- 5 Liaw YF, Sung JJ, Chow WC *et al.* Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; 351: 1521–31.
- 6 Matsumoto A, Tanaka E, Rokuhara A *et al.* Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic

- hepatitis B: a multicenter retrospective study of 2795 patients. *Hepatol Res* 2005; 32: 173–84.
- 7 Suzuki Y, Kumada H, Ikeda K *et al.* Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. *J Hepatol* 1999; 30: 743–8.
 - 8 Lok AS, Zoulim F, Locarnini S *et al.* Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. *Hepatology* 2007; 46: 254–65.
 - 9 Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. *Hepatology* 2000; 32: 635–9.
 - 10 Honkoop P, de Man RA, Heijtkink RA, Schalm SW. Hepatitis B reactivation after lamivudine. *Lancet* 1995; 346: 1156–7.
 - 11 Chang TT, Gish RG, de Man R *et al.* A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; 354: 1001–10.
 - 12 Lai CL, Shouval D, Lok AS *et al.* Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006; 354: 1011–20.
 - 13 Lai CL, Chien RN, Leung NW *et al.* A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; 339: 61–8.
 - 14 Liu F, Wang L, Li XY *et al.* Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. *J Gastroenterol Hepatol* 2011; 26: 456–60.
 - 15 Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. *Gastroenterology* 2010; 139: 491–8.
 - 16 Liaw YF, Leung N, Kao JH *et al.* Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatol Int* 2008; 2: 263–83.
 - 17 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. *Hepatol Int* 2008; 2: 163–78.
 - 18 Kumada H, Okanoue T, Onji M *et al.* Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. *Hepatol Res* 2010; 40: 1–7.
 - 19 Schuttler CG, Wend UC, Faupel FM, Lelie PN, Gerlich WH. Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). *J Clin Virol* 2010; 47: 238–42.
 - 20 Dai CY, Yu ML, Chen SC *et al.* Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. *J Clin Pathol* 2004; 57: 141–5.
 - 21 Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. *J Clin Microbiol* 2006; 44: 1390–9.
 - 22 Mizokami M, Nakano T, Orito E *et al.* Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. *FEBS Lett* 1999; 450: 66–71.
 - 23 Kimura T, Rokuhara A, Sakamoto Y *et al.* Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* 2002; 40: 439–45.
 - 24 Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. *J Med Virol* 2009; 81: 27–33.
 - 25 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009; 50: 227–42.
 - 26 Gish RG, Lok AS, Chang TT *et al.* Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. *Gastroenterology* 2007; 133: 1437–44.
 - 27 Marcellin P. Hepatitis B and hepatitis C in 2009. *Liver Int* 2009; 29 (Suppl 1): 1–8.
 - 28 Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. *Expert Rev Anti Infect Ther* 2009; 7: 633–6.
 - 29 Yokosuka O, Kurosaki M, Imazeki F *et al.* Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. *Hepatol Res* 2011; 41: 1–21.
 - 30 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; 130: 678–86.
 - 31 Chen CJ, Yang HI, Su J *et al.* Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; 295: 65–73.
 - 32 Werle-Lapostolle B, Bowden S, Locarnini S *et al.* Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. *Gastroenterology* 2004; 126: 1750–8.
 - 33 Sung JJ, Wong ML, Bowden S *et al.* Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. *Gastroenterology* 2005; 128: 1890–7.
 - 34 Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. *J Clin Microbiol* 2007; 45: 3942–7.
 - 35 Brunetto MR, Moriconi F, Bonino F *et al.* Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. *Hepatology* 2009; 49: 1141–50.
 - 36 Moucari R, Mackiewicz V, Lada O *et al.* Early serum HBsAg drop: a strong predictor of sustained virological response

- to pegylated interferon alfa-2a in HBeAg-negative patients. *Hepatology* 2009; 49: 1151–7.
- 37 Tanaka E, Matsumoto A, Yoshizawa K, Maki N. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. *Intervirolgy* 2008; 51 (Suppl 1): 3–6.
- 38 Hosaka T, Suzuki F, Kobayashi M *et al.* HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. *Liver Int* 2010; 30: 1461–70.
- 39 Matsumoto A, Tanaka E, Minami M *et al.* Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. *Hepatol Res* 2007; 37: 661–6.
- 40 Shinkai N, Tanaka Y, Orito E *et al.* Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. *Hepatol Res* 2006; 36: 272–6.

ORIGINAL ARTICLE

Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B

Yoko Tamada,^{1,2} Hiroshi Yatsuhashi,^{1,2} Naohiko Masaki,³ Makoto Nakamura,⁴ Eiji Mita,⁵ Tatsuji Komatsu,⁶ Yukio Watanabe,⁷ Toyokichi Muro,⁸ Masaaki Shimada,⁹ Taizo Hijioka,¹⁰ Takeaki Satoh,¹¹ Yutaka Mano,¹² Toshiki Komeda,¹³ Masahiko Takahashi,¹⁴ Hiroshi Kohno,¹⁵ Hajime Ota,¹⁶ Shigeki Hayashi,¹⁷ Yuzo Miyakawa,¹⁸ Seigo Abiru,^{1,2} Hiromi Ishibashi^{1,2}

For numbered affiliations see end of article.

Correspondence to

Professor Hiroshi Yatsuhashi, Clinical Research Center, NHO National Nagasaki Medical Center and Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Address: 2-1001-1 Kubara, Omura, Nagasaki 856-8562, Japan; yatsuhashi@nmc.hosp.go.jp

Revised 3 October 2011
Accepted 5 October 2011

ABSTRACT

Objective To examine recent trends of acute infection with hepatitis B virus (HBV) in Japan by nationwide surveillance and phylogenetic analyses.

Methods During 1991 through 2009, a sentinel surveillance was conducted in 28 national hospitals in a prospective cohort study. Genotypes of HBV were determined in 547 patients with acute hepatitis B. Nucleotide sequences in the preS1/S2/S gene of genotype A and B isolates were determined for phylogenetic analyses.

Results HBV genotype A was detected in 137 (25% (accompanied by genotype G in one)) patients, B in 48 (9%), C in 359 (66%), and other genotypes in the remaining three (0.5%). HBV persisted in five with genotype A including the one accompanied by genotype G; another was co-infected with HIV type 1. The genotype was A in 4.8% of patients during 1991–1996, 29.3% during 1997–2002, and 50.0% during 2003–2008 in the capital region, as against 6.5%, 8.5% and 33.1%, respectively, in other regions. Of the 114 genotype A isolates, 13 (11.4%) were subgenotype A1, and 101 (88.6%) were A2, whereas of the 43 genotype B isolates, 10 (23.3%) were subgenotype B1, 28 (65.1%) were B2, two (4.7%) were B3, and three (7.0%) were B4. Sequences of 65 (64%) isolates of A2 were identical, as were three (23%) of A1, and five (18%) of B2, but none of the B1, B3 and B4 isolates shared a sequence.

Conclusions Acute infection with HBV of genotype A, subgenotype A2 in particular, appear to be increasing, mainly through sexual contact, and spreading from the capital region to other regions in Japan nationwide. Infection persisted in 4% of the patients with genotype A, and HBV strains with an identical sequence prevailed in subgenotype A2 infections. This study indicates the need for universal vaccination of young people to prevent increases in HBV infection in Japan.

Significance of this study

What is already known about this subject?

- ▶ In Japan, a national prevention programme was started in 1986 with selective vaccination of babies born to mothers who carry hepatitis B virus (HBV). Since then, the prevalence of hepatitis B surface antigen among younger generations has decreased sharply.
- ▶ However, retrospective studies indicate that the frequency of HBV genotype A is increasing among patients with acute hepatitis B (AHB) within the capital region of Japan.
- ▶ Infection with genotype A more often persists than infection with other genotypes.
- ▶ Because there is no reliable and comprehensive surveillance system for AHB in Japan, the incidence of AHB and factors responsible for changes over many years are not known.

What are the new findings?

- ▶ This is a prospective cohort study for surveillance of AHB throughout Japan in a national research programme.
- ▶ The incidence of AHB in Japan has not decreased, because genotype A infections have increased over time.
- ▶ Genotype A infections started to increase in the capital region of Japan, and then spread to other regions 5–6 years later.
- ▶ About 90% of genotype A found in AHB patients in Japan is subgenotype A2.
- ▶ Subgenotype A2 isolates from patients with AHB tend to preserve sequence identity over time, indicating that particular subgenotype A2 strains have been transmitted without undergoing mutations.

Hepatitis B virus (HBV) has been classified into 10 genotypes, designated A–J, based on a >8% divergence in the full-genome sequence.^{1–7} Different genotypes are associated with distinct clinical manifestations, such as severity and progression of

liver disease, as well as response to antiviral treatments.^{8–10} Some genotypes are subclassified: genotype A into at least two subgenotypes, A1 (Asian/African type) and A2 (European type)^{11–13};

Viral hepatitis

Significance of this study

How might it impact on clinical practice in the foreseeable future?

- ▶ It needs to be noted that subgenotype A2 infections are spreading among sexually active generations in Japan.
- ▶ Although selective vaccination has prevented mother-to-baby transmission of HBV since 1986, it does not contain sporadic infections in Japan.
- ▶ Herd vaccination of younger generations needs to be considered in Japan.

B into B1 (Japanese type) and B2 (Asian type)^{14 15}; and C into C1 (Southeast-Asian type) and C2 (East-Asian type).¹⁶ Subgenotypes also influence the replication of HBV and clinical manifestation.^{15 17 18}

According to a report from Japan in 2001,¹⁹ genotype C was the most prevalent (84.7%), followed by genotype B (12.2%) and A (1.7%), among patients with chronic hepatitis B. In 2002, genotype A became the most prevalent in patients with acute hepatitis B (AHB) around Tokyo, the capital region of Japan.^{20 21} Several reports have shown that infection with HBV genotype A is associated with particular sexual behaviours, such as homosexual activity and promiscuous sexual contacts, and tends to persist longer than that with HBV genotype C.^{22 23} These reports have raised concerns about the horizontal HBV infection in adults, which, in general, is considered to resolve spontaneously. However, adult-acquired HBV infection may result in chronic HBV infection in some instances.

Information on changes in genotype distribution over time, as well as genotype-specific clinical manifestations, may help in planning preventive measures and antiviral therapy strategies. Therefore it is important to examine how genotype A infection has spread in Japan, and what clinical and virological characteristics it possesses.

We have been conducting a nationwide, sentinel surveillance on acute viral hepatitis for more than 30 years. As part of this surveillance, a prospective cohort study has been conducted on 547 patients with AHB in 28 medical centres over the 19 years from 1991 to 2009. Geographical and longitudinal distributions of HBV genotypes/subgenotypes were surveyed, and their influence on clinical outcome was evaluated.

PATIENTS AND METHODS

Patients

A total of 681 patients with sporadic AHB were enrolled consecutively in a survey carried out by the Japan National Hospital Acute Hepatitis Study Group (JNHAHSG). They were admitted to 28 national hospitals from January 1991 to the end of December 2009. They were grouped geographically into two areas: the capital region (Gunma, Saitama, Tokyo and Kanagawa) and other regions (figure 1). Patients were also longitudinally categorised into three periods: 1st (1991–1996), 2nd (1997–2002) and 3rd (2003–2008). In addition, the year 2009 provided the most recent data. Of the 681 patients, 547 (80.3%) entered the study, for whom serum samples were available on admission and had been stored at -20°C .

The diagnosis of AHB was based on the following criteria: (1) acute onset of liver injury without a history of liver dysfunction; (2) detection of hepatitis B surface antigen (HBsAg) in the




Figure 1 Locations of participating hospitals in Japan. Hospitals in the capital region (M1–M8) are indicated by eight closed circles, and those in other regions (O9–O28) by 20 open circles. Numbers in parentheses indicate the total number of enrolled subjects for each site. The hospitals are: M1, Nishigunma Hospital, Gunma; M2, Nishisaitama-Chuo Hospital, Saitama; M3, National Disaster Medical Center, Tokyo; M4, Tokyo Hospital, Tokyo; M5, Tokyo Medical Center, Tokyo; M6, National Center for Global Health and Medicine, Tokyo; M7, Sagami Hospital, Kanagawa; M8, Yokohama Medical Center, Kanagawa; O9, Asahikawa Medical Center, Hokkaido; O10, Hokkaido Medical Center, Hokkaido; O11, Sendai Medical Center, Miyagi; O12, Matsumoto Medical Center, Nagano; O13, Kanazawa Medical Center, Ishikawa; O14, Nagoya Medical Center, Aichi; O15, Kyoto Medical Center, Kyoto; O16, Osaka National Hospital, Osaka; O17, Osaka-Minami Medical Center, Osaka; O18, Zentsuji Hospital, Kagawa; O19, Yonago Medical Center, Tottori; O20, Okayama Medical Center, Okayama; O21, Kure Medical Center and Chugoku Cancer Center, Hiroshima; O22, Kokura Medical Center, Fukuoka; O23, Kyushu Medical Center, Fukuoka; O24, Beppu Medical Center, Oita; O25, Oita Medical Center, Oita; O26, Kumamoto Medical Center, Kumamoto; O27, Ureshino Medical Center, Saga; and O28, Nagasaki Medical Center, Nagasaki.

serum; (3) positivity for IgM antibody to HBV-core antigen (IgM anti-HBc) in high titres (detectable in sera diluted 10-fold); and (4) absence of past or family history of chronic HBV infection. Severe acute hepatitis (SAH) was defined as prothrombin time (PT) $\leq 40\%$ and hepatic encephalopathy of grade $\leq \text{I}$. Fulminant hepatitis (FH) was diagnosed from PT $\leq 40\%$ and hepatic encephalopathy of grade $\geq \text{II}$. Patients in whom HBsAg remained in the serum for >6 months after onset were considered to have acquired chronic HBV infection. The following information was collected from each patient: year and age at onset, gender, residential area, HBsAg, IgM anti-HBc, alanine aminotransferase, total bilirubin, PT, severity of liver disease, mortality, routes of transmission, sexual behaviours, travelling abroad in recent past, HBV genotype, mutations in precore (PreC) and core promoter (CP) regions, and RNA of hepatitis D virus. Antibody to HIV type 1 (anti-HIV) was

determined in patients who were at high risk and gave consent to testing.

Informed consent was obtained from each patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and the Ministry of Education, Culture, Sports Science and Technology of Japan, and was approved by the ethics committee of each institution.

Extraction of HBV DNA

HBV DNA was extracted from serum (100 µl) by the SMITEST EX-R&D Nucleic Acid Extraction Kit (MBL Co, Nagoya, Japan) and used for genotyping/subgenotyping and detecting mutations in PreC and CP regions.

HBV genotypes

Genotypes were determined in Nagasaki Medical Center with the SMITEST HBV Genotyping Kit (MBL) by hybridisation with type-specific probes immobilised on a solid-phase support.²⁴

Determination of HBV subgenotypes

For subgenotyping, HBV DNA was amplified by PCR with TaKaRa Ex Taq (Takara Bio, Shiga, Japan). PCR was performed with appropriate nested primers to amplify a ~1.2 kb sequence in the preS1/S2/S gene (nucleotides 2854–835 in the reference isolate (AB116077)). PCR products were purified, subjected to cycle sequencing reaction with the BigDye Terminator v1.1 (Applied Biosystems, Tokyo, Japan), and applied to the DNA sequencer (3100-Avant; Applied Biosystems).

Mutations in the PreC and CP regions

The A1896 mutation in the PreC region was detected by the enzyme-linked minisequence assay (SMITEST HBV PreC ELMA; Roche Diagnostics, Tokyo, Japan), and mutations in the CP region for T1762/A1764 by the enzyme-linked specific probe assay (SMITEST HBV Core Promoter Mutation Detection Kit; Roche Diagnostics). The results were recorded as 'wild-type' and 'mutant types' dominantly expressed by HBV isolates.²⁵

Phylogenetic analyses

Nucleotide sequences were aligned, and phylogenetic trees were constructed by the CLUSTAL W program v1.83 (DDBJ homepage: <http://clustalw.ddbj.nig.ac.jp/top-j.html>). The statistical validity was assessed by bootstrap resampling with 1000 replicates. Reference HBV strains were retrieved from the GenBank database.

Statistical analysis

Results were expressed as percentage or mean±SD. Statistical differences were evaluated by χ^2 and Fisher exact tests for categorical variables, and analysis of variance and Scheffe's test for quantitative variables, using the SPSS software. The 95% CI, for the difference in means, was calculated in analyses for quantitative variables. $p < 0.05$ was considered significant.

RESULTS

Distribution of HV genotypes

HBV genotypes were determined in the 547 patients with AHB. The genotype was A in 137 (25.0%) patients (accompanied by G in one (0.2%)), B in 48 (8.8%), C in 359 (65.6%), D in one (0.2%), E in one (0.2%), and H in one (0.2%). Because HBV genotype G is a defective virus and cannot replicate by itself,^{26 27} the single patient with mixed genotypes A and G was included in the 137 patients with genotype A in further analyses. RNA of hepatitis

D virus was detected in three of the 453 (0.7%) patients. Anti-HIV was examined in patients at high risk of infection and detected in 14 of the 53 (26.4%) who gave consent to testing.

Demographic and clinical differences among patients infected with HBV of distinct genotypes

Demographic and clinical characteristics of patients with different genotypes are compared in table 1. There was no difference in mean age among patients with genotypes A, B and C. The proportion of men was higher in patients with genotype A than B or C (94.2% vs 79.2%, $p < 0.05$; or 56.0%, $p < 0.0001$), and in those with genotype B than C (79.2% vs 56.0%, $p < 0.05$).

Maximum levels of total bilirubin were higher in patients with genotype A than C (9.6 ± 7.6 vs 7.1 ± 6.2 mg/dl, $p < 0.05$), with a difference of 2.5 mg/dl (95% CI 0.93 to 4.08), whereas the highest alanine aminotransferase activity and lowest PT values did not differ among patients with distinct genotypes.

SAH developed in four (2.9%) patients with genotype A, four (8.3%) with genotype B, and 26 (7.2%) with genotype C. FH developed in one (2.1%) patient with genotype B and eight (2.2%) with genotype C; no patients with genotype A developed FH. Eight (1.5%) patients died, including one with genotype B and seven with genotype C. There were no significant differences among patients with different genotypes in the frequency of SAH or FH or mortality.

The outcome of AHB was traceable in 514 of the 547 (94.0%) patients. Chronic infection with persistence of HBsAg for >6 months developed in five of the 123 (4.1%) patients with genotype A (including the one accompanied by genotype G), none of the 46 (0%) with genotype B, and none of the 342 (0%) with genotype C; it was more common in patients with genotype A than C ($p < 0.05$). HBV infection persisted exclusively in the patients with genotype A, either alone (four patients) or together with genotype G (one).

Among the five patients who acquired chronic HBV infection, four (three with genotype A and one with mixed genotypes A and G) were examined for anti-HIV, and one with genotype A was found to be positive. HBV infection persisted in three (including the one with anti-HIV) of the five patients for >1 year after the onset, and the remaining two (both without anti-HIV) cleared HBsAg from the serum after retaining it for >6 months.

Mutations in the PreC and/or CP region were detected in 3.7% (4/109) of patients with genotype A, 15.4% (6/39) of those with genotype B, and 25.5% (79/310) of those with genotype C. They were significantly less common in patients with genotype A than B or C (A vs B, $p < 0.05$; A vs C, $p < 0.0001$). The only patient with genotype A who had the PreC mutation was simultaneously infected with genotype G.

Routes of transmission were identifiable in 275 of the 547 (50%) patients, and the main route was heterosexual contacts; those in the remaining patients could not be disclosed. The frequency of heterosexual activity did not differ among patients with distinct genotypes. However, homosexual activity was more common in patients with genotype A than B or C (21.2%, 0% and 0.8%, respectively (A vs B, $p < 0.001$; A vs C, $p < 0.0001$)). Among the 32 homosexual men, HBV genotype A was detected in 29 (91%). Consent to anti-HIV testing was given by 10 of the 29 patients, and four of these (40%) were positive.

Longitudinal changes in the distribution of genotypes

Figure 2 illustrates changes in the distribution of HBV genotypes through three 6-year periods over 18 years (1991–2008). In addition, data from 2009 are shown. HBV genotype A accounted

Viral hepatitis

Table 1 Demographic and clinical characteristics of patients with acute hepatitis who were infected with HBV of different genotypes (1991–2009)

Feature	Total (n=547)	HBV genotypes			
		A (n=137)† (25.0%)	B (n=48) (8.8%)	C (n=359) (65.6%)	Others (n=3)‡ (0.5%)
Age (years)	35.6±14.8	35.2±12.2	39.6±15.6	35.1±15.5	49.7±13.6
Male	367 (67.1%)	129 (94.2%)¶ * †† ***	38 (79.2%)†† *	201 (56.0%)	3 (100%)
ALT (IU/l)§	2553±1563	2289±1069	2557±1412	2342±1728	3333±2406
T-Bil (mg/dl)§	7.8±6.7	9.6±7.6††*	7.7±7.4	7.1±6.2	9.0±2.5
PT (%)§	74.6±22.6	75.2±15.9	73.8±24.5	74.7±24.5	15.8‡‡
Severe hepatitis	34 (6.2%)	4 (2.9%)	4 (8.3%)	26 (7.2%)	0 (0.0%)
Fulminant hepatitis	10 (1.8%)	0 (0.0%)	1 (2.1%)	8 (2.2%)	1 (33.3%)
Mortality	8 (1.5%)	0 (0.0%)	1 (2.1%)	7 (1.9%)	0 (0.0%)
HBsAg persisting >6 months	5/514 (1.0%)	5/123 (4.1%)†† *	0/46 (0.0%)	0/342 (0%)	0/3 (0.0%)
PreC/CP mutations					
PreC	43/461 (9.3%)	1/109 (0.9%)¶ * †† *	6/39 (15.4%)	34/310 (11.0%)	2/3 (66.7%)
CP	69/461 (15.0%)	3/109 (2.8%)†† ***	0/39 (0.0%)†† *	63/310 (20.3%)	3/3 (100%)
PreC and/or CP	92/461 (20.0%)	4/109 (3.7%)¶ * †† ***	6/39 (15.4%)	79/310 (25.5%)	3/3 (100%)
Transmission route					
Homosexual	32 (5.9%)	29 (21.2%)¶ ** †† ***	0 (0.0%)	3 (0.8%)	0 (0.0%)
Heterosexual	217 (39.5%)	52 (38.0%)	25 (52.1%)	139 (39.6%)	1 (33.3%)
Medical procedure	16 (2.9%)	2 (1.5%)	2 (4.2%)	12 (3.3%)	0 (0.0%)
Other	10 (1.8%)	1 (0.7%)	1 (2.1%)	7 (1.9%)	1 (33.3%)
Undetermined	272 (49.7%)	53 (38.7%)†† *	20 (41.7%)	198 (55.2%)	1 (33.3%)
Anti-HIV	14/53 (26.4%)	11/35 (31.4%)	0/3 (0.0%)	3/15 (20.0%)	0/0

Values are mean±SD or number (%).

†One patient with genotype A was simultaneously infected with genotype G.

‡Each patient was infected with genotype D, E or H.

§Highest values during the clinical course are shown for ALT and T-Bil, and lowest values for PT.

Statistical analysis was performed to compare genotypes A, B and C.

¶Significantly different compared with genotype B.

††Significantly different compared with genotype C.

*p<0.05, **p<0.001, ***p<0.0001.

‡‡Data from the patient with genotype E only.

ALT, alanine aminotransferase; CP, core promoter; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PreC, precore; PT, prothrombin time; T-Bil, total bilirubin.

for 6% (9/150) in the 1st period, 15.4% (19/123) in the 2nd, and 39.4% (89/226) in the 3rd, with significant differences between 1st and 2nd (p<0.05), 2nd and 3rd (p<0.0001), and 1st and 3rd (p<0.0001). Conversely, AHB associated with genotype C decreased through three periods with significant differences, while AHB associated with genotype B did not change appreciably.

On the basis of these results, the yearly incidence in each of the three 6-year periods is calculated to be: 25.0 cases including 1.5 with genotype A in the 1st period; 20.5 cases including 3.2 with genotype A in the 2nd; and 37.7 cases including 14.8 with genotype A in the 3rd. Hence, the incidence of AHB had not changed markedly over the 12 years from 1991 to 2002, but increased thereafter until 2008. Of the increment in the 3rd period of 17.2 (37.7 minus 20.5) cases, there were 11.6 (14.8 minus 3.2) with genotype A; they accounted for 67% (11.6/17.2) of the recent increase in AHB.

Regional distributions and longitudinal changes in genotype A

Among the 183 patients from the capital region, the genotype was A in 65 (35.5%), B in 22 (12.0%), C in 94 (51.4%), E in one (0.5%), and H in one (0.5%) (table 2). Of the remaining 364 (66.5%) patients from other regions, by contrast, the genotype was A in 72 (19.8%), B in 26 (7.1%), C in 265 (72.8%), and D in one (0.3%). Genotype A was significantly more common in the capital than in other regions (35.5% vs 19.8%, p<0.0001). In the capital region, genotype A accounted for 4.8% (2/42) in the 1st period, 29.3% (12/41) in the 2nd, and 50.0% (42/84) in the 3rd. There were significant differences between the 1st and 2nd periods (p<0.05), 2nd and 3rd (p<0.05), and 1st and 3rd (p<0.0001). In other regions, by contrast, genotype A accounted for 6.5% (7/108) in the 1st period, 8.5% (7/182) in the 2nd, and

33.1% (47/142) in the 3rd. For the first time in other regions, genotype A increased in the 3rd period, in comparison with the 1st and 2nd (1st vs 3rd, p<0.0001; 2nd vs 3rd, p<0.0001).


Subgenotypes of genotype A

Of the 137 genotype A isolates, amplification and sequencing of HBV DNA were feasible in 114 (83.2%); the isolate from the single patient with genotypes A and G was excluded. A phylogenetic tree was constructed, on the entire preS1/S2/S genes of ~1.2 kb, for these 114 isolates along with 34 genotype A isolates retrieved from the database (figure 3).

Of the 114 isolates in this study, 101 (88.6%) were subgenotype A2, and the remaining 13 (11.4%) were subgenotype A1. In a pair-wise comparison, the sequence divergence among the 101 subgenotype A2 isolates was 0–1.3%, and that among the 13 subgenotype A1 isolates spanned 0% to 2.3%. The sequence divergence between subgenotype A2 and A1 isolates ranged from 2.6% to 4.7%.

A sequence of 1203 nucleotides was possessed in common by three of the 101 (3%) isolates of subgenotype A2. For convenience, the group comprising these three isolates was labelled 'identical group I'. Likewise, an additional six 'identical groups' were found, and numbered from 'II' to 'VII'. They comprised 35 (35%), seven (7%), two (2%), three (3%), 12 (12%) and three (3%) of the 101 isolates of subgenotype A2. In contrast, only one identical group, designated 'VIII', was constructed by three of the 13 (23%) isolates of subgenotype A1.

Some isolates of subgenotype A1 and A2 were obtained from patients who had travelled to foreign countries in the recent past (5/13 (38.5%) patients with A1 to Africa, Philippines, Myanmar and China; and 5/101 (5.0%) patients with A2 to Europe, Thailand, Brazil and the USA).

Figure 2 Distribution of hepatitis B virus (HBV) genotypes in three periods.**Subgenotypes of genotype B**

Of the 48 isolates of genotype B, subgenotyping was feasible in 43 (90.0%). A phylogenetic tree was constructed on preS1/S2/S-gene sequences from these 43 isolates, along with those from 25 isolates of genotype B retrieved from the database (figure 4). Of the 43 isolates in this study, 10 (23.3%) were subgenotype B1, 28 (65.1%) were B2, two (4.7%) were B3, and three (7.0%) were B4. In a pair-wise comparison, the sequence divergence among 10 subgenotype B1 isolates ranged from 0.4% to 1.4%, and that among 28, two and three isolates of subgenotypes B2, B3 and B4 spanned 0–1.7%, 0.5% and 0.6–0.8%, respectively. The inter-subgenotype divergence among B1–B4 ranged from 0.6% to 4.4%.

One 'identical group' made up of five isolates was detected among the 28 of subgenotype B2; it was named 'IX'. In contrast, no 'identical group' was found in 10, two or three isolates of subgenotype B1, B3 or B4.

Some isolates of subgenotypes B2, B3 and B4 were obtained from patients who had travelled to foreign countries in the recent past (7/28 (25.0%) patients with B2 to China and other countries; 1/2 (50.0%) patients with B3 to a country unknown; and 1/3 (33.3%) patients with B4 to Vietnam). However, none of the 10 subgenotype B1 isolates was associated with travel to foreign countries.

Identical groups

The proportion of isolates that shared a sequence in identical groups was higher for subgenotype A2 (64.4%) than for A1, B1, B2, B3 or B4 (23.1%, 0%, 17.9%, 0% or 0%, respectively (A2 vs A1, $p < 0.001$; A2 vs B1, $p < 0.0001$; A2 vs B2, $p < 0.0001$)).

Homosexual activity was more common in patients belonging to the seven identical groups than the non-identical group of subgenotype A2 (17/65 (26.2%) vs 3/36 (8.3%), $p < 0.05$). Among the isolates in the seven identical groups of subgenotype A2, those in groups I, III and VII clustered locally during short periods of 2–7 years. In contrast, subgenotype A2 isolates in groups II and VI were scattered widely over longer periods of 11–16 years.

DISCUSSION

In Japan, as in most Asian countries, the persistent HBV carrier state had been established mainly through perinatal transmission from mother to baby and horizontal infection during infancy. In 1986, a national prevention programme was launched in Japan with selective vaccination of babies born to carrier mothers with hepatitis B e antigen (HBeAg). In 1995, this was extended to babies born to HBeAg-negative carrier mothers. As a result, the prevalence of HBsAg among younger people born since 1986 has decreased dramatically.^{28 29} However, there are an

Table 2 Changes in the distribution of genotype A compared between the capital region and other regions over three periods

Area	n	1st Period (1991–1996)	2nd Period (1997–2002)	3rd Period (2003–2008)	2009
Capital region	65/183 (35.5%)†***	2/42 (4.8%)‡* §***	12/41 (29.3%)†* §*	42/84 (50.0%)†*	9/16 (56.3%)
Other regions	72/364 (19.8%)	7/108 (6.5%)§***	7/82 (8.5%)§***	47/142 (33.1%)	11/32 (34.4%)
Total	137/547 (25.0%)	9/150 (6.0%)‡* §***	19/123 (15.4%)§***	89/226 (39.4%)	20/48 (41.7%)

Statistical analysis of the differences between the capital and other regions was performed, as well as through the 1st, 2nd and 3rd periods.

†Significantly different compared with other regions.


‡Significantly different compared with the 2nd period.

§Significantly different compared with the 3rd period.

* $p < 0.05$, *** $p < 0.0001$.

Viral hepatitis

Figure 3 Phylogenetic analysis of genotype A strains by the neighbour-joining method. Isolates obtained in this study are shown in bold with asterisks. Hospitals in the capital region are labelled M1–M8 and those in other regions 09–028 (corresponding to those in figure 1). Year of onset is indicated by the last two digits after the first hyphen. Numbers after the second hyphen represent the identification numbers of patients in each year (not always consecutive). Transmission routes are shown in lower-case letters in parentheses: h, homosexual; s, heterosexual; m, medical procedure; o, others; and u, undetermined. Isolates with identical sequences are bracketed in 'Identical groups I through VIII' on the tree. Each bracket is divided by areas and periods. Reference hepatitis B virus (HBV) isolates, including 12 of subgenotype A1 and 22 of subgenotype A2, were obtained from the database and specified by their accession numbers, isolate names and countries of origin. Bootstrap values are indicated on major phylogenetic branches.




estimated one million HBV carriers in Japan at present.³⁰ Furthermore, many Japanese remain at increased risk of horizontal infection with HBV, because they have not received selective vaccination and therefore do not have the antibody to HBsAg. Because AHB is extremely under-reported and no national surveillance data are available in Japan, the incidence has not been determined accurately. In the USA, the incidence of AHB has decreased markedly since the adoption of a comprehensive immunisation strategy in 1991.^{31 32}

In the present study over 1991–2009, we conducted a nationwide, sentinel surveillance on AHB in Japan. In the 547 patients recruited over 19 years, genotype C was the most prevalent (65.6%), followed by genotype A (25.0%) and genotype B (8.8%). Demographic and clinical differences were observed among patients with genotypes A, B and C (table 1).

The proportion of men reached 94.2% for genotype A infection, higher than that for genotype B (79.2%) or C (56.0%) infection. In the analysis of the route of transmission, homosexual activity was reported by 21.2% of patients with genotype A; all were male. In general, sexual activity tends to be higher in men than women. The predominance of genotype A in men may be attributable to a high frequency of homosexual activity among men.

Although adult-acquired HBV infection persists at a high frequency of ~10% in European countries and the USA,³³ it rarely, if ever, becomes chronic in Japan. Recent studies suggest that the chance of a chronic outcome of AHB may differ by HBV genotype^{21 34}; it is more common for genotype A than other genotypes.^{22 35 36} In the present study, HBV infection persisted in 4.1% of patients with genotype A, in comparison with 0% of

Figure 4 Phylogenetic analysis of genotype B strains by the neighbour-joining method. Hepatitis B virus (HBV) isolates obtained in the present study are specified in the same manner as in figure 3, and isolates with an identical sequence are bracketed in 'Identical group IX' on the tree. Of them, 10 reference isolates of subgenotype B1 and 13, two and two of those of B2, B3 and B4, respectively, were retrieved from the database; they are specified as in figure 3.



those with genotype C. Remarkably, all five patients with AHB who acquired chronic infection possessed HBV genotype A, either alone (four patients) or together with HBV genotype G (one). Increasing genotype A infections may have changed the genotype distribution in patients with AHB and those with chronic HBV infection. In Japanese patients with chronic hepatitis B, the proportion of genotype A has doubled, from 1.7% in 1999–2000 to 3.5% in 2005–2006.⁵⁷

The genotype was A in 29 of the 32 (91%) homosexual men. Of the 29 homosexuals with genotype A, 10 gave consent to anti-HIV testing, and four of these (40%) were found to be positive. Of the five patients who acquired chronic HBV infection, anti-HIV was tested in four (three with genotype A and one with genotypes A and G), and one with genotype A was found to be positive. There is a possibility that co-infecting HIV in this patient with genotype A may have promoted chronic

HBV infection; HIV is known to prolong and aggravate HBV infection by compromising immune responses.³⁸

Patients with FH in this study were infected with either HBV genotype B (1/48 (2.1%)) or C (8/359 (2.2%)); no patients with genotype A developed FH. PreC and/or CP mutations were significantly less common in genotype A (1/109 (3.7%)) than B (6/39 (15.4%)) or C (279/310 (5.5%)) infection. The single patient with genotype A who had PreC mutation was simultaneously infected with HBV genotype G. There is a possibility that the PreC mutation in this patient was from HBV genotype G.²⁶ FH did not develop in any patients with genotype A, which may be attributable, at least in part, to the lack of PreC mutation in genotype A infections.³⁹

Previous reports have shown that genotype A is common in patients with AHB in Metropolitan Tokyo,^{20 21 40} as well as around Aichi located in the middle of Mainland Japan.²²

Viral hepatitis

Yotsuyanagi *et al*²³ reported that genotype A is more common in patients with AHB in the metropolitan region than in other regions. Sugauchi *et al*⁴¹ found that, in patients with AHB, the proportion with genotype A has increased over time. The present study indicates that the number of patients with AHB in Japan would not have decreased. We found that the proportion of patients with genotype A infection is increasing in the 28 national hospitals in Japan (6.0% in the 1st period, 15.4% in the 2nd, and 39.4% in the 3rd (figure 2)), with the prevalence much higher in the capital than other regions (35.5% vs 19.8% (table 2)).

In this study, there was a time lag in the increase in genotype A infection between the capital region and other regions of Japan (table 2). In the capital region, the prevalence of genotype A started to increase in the late 1990s, and kept increasing through the early 2000s (4.8% in the 1st period, 29.3% in the 2nd, 50.0% in the 3rd, and 56.3% in 2009). In other regions, by contrast, the frequency of genotype A did not change during the late 1990s, and increased significantly in the 2000s (6.5% in the 1st period, 8.5% in the 2nd, 33.1% in the 3rd, and 34.4% in 2009). Thus infiltration of genotype A infection into other regions occurred 5–6 years behind the epidemic in the capital region. This indicates that genotype A infection originated in the capital region and then spread to other areas of Japan.

Some genotypes are classified into several subgenotypes, and they have distinct geographical distributions.⁴² Hence, subgenotypes are useful in tracing the route of HBV infection. By phylogenetic analysis (figures 3 and 4), 88.6% of genotype A isolates had the European–American type (A2), and the remaining 11.4% possessed the Asian–African type (A1). Likewise, 76.7% of genotype B isolates had Asian types (B2–B4), and the remaining 23.3% possessed the type endemic to Japan (B1). Of the 157 HBV isolates of genotype A or B, 147 (93.6%) had subgenotypes foreign to Japan. They are thought to have been transmitted from foreign sex workers, and spread among certain populations who share particular sexual behaviours in Japan.⁴¹

Of note, some HBV isolates of distinct subgenotypes possessed an identical sequence in the preS1/S2/S gene. The isolates of subgenotype A2 were prominent in this regard, and more often had the same sequence than those of other subgenotypes, such as A1, B1 and B2. The high prevalence of subgenotype A2 isolates with an identical sequence would not have been caused by cross-contamination. If cross-contamination had occurred, it would have affected isolates of all subgenotypes, and not influenced subgenotype A2 isolates preferentially. As many as 35% of subgenotype A2 isolates had an identical sequence, and those with the same sequence increased to 56.3% in the recent 2009 survey in Metropolitan Tokyo. Furthermore, some subgenotype A2 isolates in groups I, III and VII clustered locally within short periods, whereas others in groups II and VI were scattered widely over a long period of time. On the basis of these results, it is tempting to speculate that some subgenotype A2 strains would have been transmitted from person to person without undergoing mutations for many years.

In summary, the present study indicates the following. (1) AHB in the 28 national hospitals in Japan has not decreased, because genotype A infections are increasing. (2) Genotype A infections started to increase in the capital region, and then spread to local areas 5–6 years later. (3) Approximately 90% of genotype A in patients with AHB is subgenotype A2. (4) Subgenotype A2 strains with an identical sequence are spreading among younger generations with high sexual activity. (5) On the basis of the results obtained, AHB in Japan is not decreasing, because HBV of subgenotype A2 is prevailing in particular

subpopulations at high risk. Finally, in order to prevent further increases in AHB in Japan, universal vaccination of young people deserves consideration.

Author affiliations

- ¹Clinical Research Center, NHO Nagasaki Medical Center, Nagasaki, Japan
- ²Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- ³National Center for Global Health and Medicine, Tokyo, Japan
- ⁴NHO Kyushu Medical Center, Fukuoka, Japan
- ⁵NHO Osaka National Hospital, Osaka, Japan
- ⁶NHO Yokohama Medical Center, Kanagawa, Japan
- ⁷NHO Sagami Hospital, Kanagawa, Japan
- ⁸NHO Oita Medical Center, Oita, Japan
- ⁹NHO Nagoya Medical Center, Aichi, Japan
- ¹⁰NHO Osaka-Minami Medical Center, Osaka, Japan
- ¹¹NHO Kokura Medical Center, Fukuoka, Japan
- ¹²NHO Sendai Medical Center, Miyagi, Japan
- ¹³NHO Kyoto Medical Center, Kyoto, Japan
- ¹⁴NHO Tokyo Medical Center, Tokyo, Japan
- ¹⁵NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan
- ¹⁶NHO Kanazawa Medical Center, Ishikawa, Japan
- ¹⁷NHO National Disaster Medical Center, Tokyo, Japan
- ¹⁸Miyakawa Memorial Research Foundation, Tokyo, Japan

Acknowledgements We thank participating physicians (MD) in the JNHAHSG for collaborating, with data and sample collection: Hideo Nishimura, Asahikawa Medical Center; Yukio Ohhara, Hokkaido Medical Center; Masakazu Kobayashi, and the late Takeshi Sodeyama, Matsumoto Medical Center; Fujio Makita, Nishigunma Hospital; Takeo Saoshiro, and Akira Saito, Nishisaitama-Chuo Hospital; Michiyasu Yagura, and the late Hideharu Harada, Tokyo Hospital; Keiichi Hirata, National Disaster Medical Center; Yoko Nakamura, Sagami Hospital; the late Hideo Morimoto, Kanazawa Medical Center; Noboru Hirashima, Higashi Nagoya National Hospital; Michio Kato, Osaka National Hospital; Tetsuo Yamamoto, Yonago Medical Center; Haruhiro Yamashita, Okayama Medical Center; Hirota Kouno and Eiichi Takezaki, Kure Medical Center and Chugoku Cancer Center; Toru Hayashi, and Shuji Oda, Zentsuji Hospital; Akihito Masumoto, Kokura Medical Center; Hironori Sakai, Beppu Medical Center; Koichi Honda, Oita Medical Center; Kazuhiro Sugi, Kumamoto Medical Center; Michiaki Koga, and Hiroaki Kawasoe, Ureshino Medical Center; Michitami Yano, and Manabu Daikoku, Nagasaki Medical Center. All the hospitals belong to National Hospital Organization (NHO). We appreciate the excellent technical assistance of Ms Rumiko Hamada, Ms Yuka Jiuchi, Ms Mika Fukuda and Ms Rumiko Nakao. Finally, we express our deep gratitude to the late Dr Koji Yano (Nagasaki Medical Center) for his contribution to the design and coordination of this study, and we dedicate this article to him.

Funding This study was supported by a grant-in-aid from the National Hospital Organization (grant number H21-NHO(Kan)-03).

Competing interests None.

Ethics approval Approved by the ethics committee of each institution.

Contributors YT, HY and HI designed data collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned and analysed the data. YT, HY and YM drafted and revised the paper. HY, NM, MN, EM, TK, YW, TM, MS, TH, TS, YM, TK, MT, HK, HO, SH and SA collaborated in data and sample collection.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Arauz-Ruiz P, Norder H, Robertson BH, *et al*. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002;**83**:2059–73.
2. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* 1994;**198**:489–503.
3. Okamoto H, Tsuda F, Sakugawa H, *et al*. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. *J Gen Virol* 1988;**69**:2575–83.
4. Olinger CM, Jutavijittum P, Hubschen JM, *et al*. Possible new hepatitis B virus genotype, southeast Asia. *Emerg Infect Dis* 2008;**14**:1777–80.
5. Stuyver L, De Gendt S, Van Geyt C, *et al*. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *J Gen Virol* 2000;**81**:67–74.
6. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. *J Virol* 2008;**82**:5657–63.
7. Tatematsu K, Tanaka Y, Kurbanov F, *et al*. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol* 2009;**83**:10538–47.

8. **Chu CJ**, Lok AS. Clinical significance of hepatitis B virus genotypes. *Hepatology* 2002;**35**:1274–6.
9. **Kao JH**. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. *J Gastroenterol Hepatol* 2002;**17**:643–50.
10. **Miyakawa Y**, Mizokami M. Classifying hepatitis B virus genotypes. *Intervirology* 2003;**46**:329–38.
11. **Kimbi GC**, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. *J Gen Virol* 2004;**85**:1211–20.
12. **Kramvis A**, Weitzmann L, Owiredu WK, *et al*. Analysis of the complete genome of subgroup A' hepatitis B virus isolates from South Africa. *J Gen Virol* 2002;**83**:835–9.
13. **Sugauchi F**, Kumada H, Acharya SA, *et al*. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 2004;**85**:811–20.
14. **Sugauchi F**, Kumada H, Sakugawa H, *et al*. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. *Clin Infect Dis* 2004;**38**:1222–8.
15. **Sugauchi F**, Orito E, Ichida T, *et al*. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. *Gastroenterology* 2003;**124**:925–32.
16. **Tanaka Y**, Orito E, Yuen MF, *et al*. Two subtypes (subgenotypes) of hepatitis B virus genotype C: a novel subtyping assay based on restriction fragment length polymorphism. *Hepatal Res* 2005;**33**:216–24.
17. **Akuta N**, Suzuki F, Kobayashi M, *et al*. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. *J Hepatol* 2003;**38**:315–21.
18. **Tanaka Y**, Hasegawa I, Kato T, *et al*. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. *Hepatology* 2004;**40**:747–55.
19. **Orito E**, Ichida T, Sakugawa H, *et al*. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001;**34**:590–4.
20. **Kobayashi M**, Arase Y, Ikeda K, *et al*. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 2002;**68**:522–8.
21. **Ogawa M**, Hasegawa K, Naritomi T, *et al*. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. *Hepatal Res* 2002;**23**:167–77.
22. **Takeda Y**, Katano Y, Hayashi K, *et al*. Difference of HBV genotype distribution between acute hepatitis and chronic hepatitis in Japan. *Infection* 2006;**34**:201–7.
23. **Yotsuyanagi H**, Okuse C, Yasuda K, *et al*. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *J Med Virol* 2005;**77**:39–46.
24. **Kato H**, Orito E, Sugauchi F, *et al*. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. *J Virol Methods* 2003;**110**:29–35.
25. **Orito E**, Mizokami M, Sakugawa H, *et al*. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 2001;**33**:218–23.
26. **Kato H**, Orito E, Gish RG, *et al*. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. *Hepatology* 2002;**35**:922–9.
27. **Sugiyama M**, Tanaka Y, Sakamoto T, *et al*. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfecting with genotype G. *Hepatology* 2007;**45**:929–37.
28. **Koyama T**, Matsuda I, Sato S, *et al*. Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy. *Hepatal Res* 2003;**26**:287–92.
29. **Noto H**, Terao T, Ryou S, *et al*. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980–1994. *J Gastroenterol Hepatol* 2003;**18**:943–9.
30. **Tanaka J**, Kumagai J, Katayama K, *et al*. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. *Intervirology* 2004;**47**:32–40.
31. **Daniels D**, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. *MMWR Surveill Summ* 2009;**58**:1–27.
32. **Goldstein ST**, Alter MJ, Williams IT, *et al*. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. *J Infect Dis* 2002;**185**:713–19.
33. **Sherlock S**. The natural history of hepatitis B. *Postgrad Med J* 1987;**63** Suppl 2:7–11.
34. **Mayerat C**, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? *J Viral Hepat* 1999;**6**:299–304.
35. **Hayashi K**, Katano Y, Takeda Y, *et al*. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. *J Gastroenterol* 2008;**43**:558–64.
36. **Ozasa A**, Tanaka Y, Orito E, *et al*. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* 2006;**44**:326–34.
37. **Matsuura K**, Tanaka Y, Hige S, *et al*. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* 2009;**47**:1476–83.
38. **Bodsworth NJ**, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *J Infect Dis* 1991;**163**:1138–40.
39. **Li JS**, Tong SP, Wen YM, *et al*. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. *J Virol* 1993;**67**:5402–10.
40. **Suzuki Y**, Kobayashi M, Ikeda K, *et al*. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol* 2005;**76**:33–9.
41. **Sugauchi F**, Orito E, Ohno T, *et al*. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatal Res* 2006;**36**:107–14.
42. **Norder H**, Courouce AM, Coursaget P, *et al*. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004;**47**:289–309.



Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B

Yoko Tamada, Hiroshi Yatsunami, Naohiko Masaki, et al.

Gut published online November 7, 2011

doi: 10.1136/gutjnl-2011-300832

Updated information and services can be found at:

<http://gut.bmj.com/content/early/2011/11/07/gutjnl-2011-300832.full.html>

These include:

References

This article cites 42 articles, 13 of which can be accessed free at:

<http://gut.bmj.com/content/early/2011/11/07/gutjnl-2011-300832.full.html#ref-list-1>

P<P

Published online November 7, 2011 in advance of the print journal.

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>

Original Article

Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B

Takashi Toyama,¹ Hisashi Ishida,¹ Hiromi Ishibashi,² Hiroshi Yatsushashi,² Makoto Nakamura,³ Masaaki Shimada,⁴ Hajime Ohta,⁵ Takeaki Satoh,⁶ Michio Kato,⁷ Taizo Hijioka,⁸ Hirotugu Takano,⁹ Toshiki Komeda,¹⁰ Michiyasu Yagura,¹¹ Hiroshi Mano,¹² Yukio Watanabe,¹³ Masakazu Kobayashi¹⁴ and Eiji Mita¹

¹Department of Gastroenterology and Hepatology, NHO, Osaka National Hospital, Osaka, ²Department of the Clinical Research Center, NHO, Nagasaki Medical Center, Nagasaki, ³Department of Gastroenterology, NHO, Kyushu Medical Center, Kyushu, ⁴Department of Gastroenterology, NHO, Nagoya Medical Center, Nagoya, ⁵Department of Gastroenterology, NHO, Kanazawa Medical Center, Kanazawa, ⁶Center for Liver Disease, NHO, Kokura Medical Center, Kokura, ⁷Department of Hepatology, NHO, Minamiwakayama Medical Center, Minamiwakayama, ⁸Department of Gastroenterology, NHO, Osaka Minami Medical Center, Osaka, ⁹Department of Gastroenterology, NHO, Kure Medical Center, Kure, ¹⁰Department of Gastroenterology, NHO, Kyoto Medical Center, Kyoto, ¹¹Department of Gastroenterology, NHO, Tokyo National Hospital, Tokyo, ¹²Department of Gastroenterology, NHO, Sendai Medical Center, Sendai, ¹³Department of Gastroenterology, NHO, Sagami National Hospital, Sagami, and ¹⁴Department of Gastroenterology, NHO, Matsumoto Medical Center, Matsumoto, Japan

Aim: Add-on adefovir dipivoxil (ADV) therapy has been a standard rescue treatment for patients with lamivudine (LAM)-resistant chronic hepatitis B, but the overall benefits of long-term add-on ADV therapy are still limited. The aim of this study was to evaluate the long-term efficiency of add-on ADV treatment and to explore predictive factors associated with it.

Methods: A total of 158 patients with LAM-resistant chronic hepatitis B were included in this retrospective, multicenter, nationwide study in Japan. After confirming LAM resistance, ADV was added to LAM treatment. Three types of events were considered as outcomes: virological response, hepatitis B e antigen (HBeAg) clearance and alanine aminotransferase (ALT) normalization. Virological response was defined as serum hepatitis B virus (HBV) DNA levels of less than 3 log copies/mL. Baseline factors contributing to these outcomes were examined by univariate and multivariate analyses.

Results: The median total duration of ADV treatment was 41 months (range, 6–84). The rate of virological response was

90.8% at 4 years of treatment; HBeAg clearance and ALT normalization were achieved by 34.0% and 82.7%, respectively, at the end of follow up. Each outcome had different predictive factors: baseline HBV DNA and albumin level were predictive factors for virological response, history of interferon therapy and ALT level for HBeAg clearance, and sex and baseline albumin level for ALT normalization.

Conclusion: Long-term add-on ADV treatment was highly effective in LAM-resistant chronic hepatitis B patients in terms of virological and biochemical responses. Lower HBV replication and lower albumin level at baseline led to better outcomes.

Key words: adefovir dipivoxil, alanine aminotransferase normalization, chronic hepatitis B, hepatitis B e antigen clearance, lamivudine resistance, virological response

Correspondence: Dr Eiji Mita, Department of Gastroenterology and Hepatology, NHO, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006, Japan. Email: ejim67@onh.go.jp
Received 29 January 2012; revision 11 April 2012; accepted 15 April 2012.

INTRODUCTION

CHRONIC HEPATITIS B (CHB) is an important cause of morbidity and mortality worldwide.^{1–3} The main goals of therapy in CHB patients are to prevent the development of liver failure, due to subsequent liver

cirrhosis, and the emergence of hepatocellular carcinoma (HCC). All of these are likely to be achieved by suppressing hepatitis B virus (HBV) replication, which thereby leads to remission of liver disease.⁴

Lamivudine (LAM) treatment has been used to prevent the progression of CHB and the development of HCC.⁵ LAM is an effective and well-tolerated treatment for patients with CHB, but it has the major limitation of drug-resistant mutants arising at a rate of 16–32% during the first year of treatment and increasing by 15% with each additional year of treatment.^{6–8} The widespread use of LAM monotherapy in CHB patients before introduction of entecavir, which is more potent, has progressively increased the numbers of patients with LAM-resistant HBV mutant strains.

Adefovir dipivoxil (ADV) has been reported to be effective in suppressing HBV replication and approved as a standard therapy in LAM-resistant patients.^{9,10} However, data concerning the long-term efficacy of ADV treatment in LAM-resistant CHB patients are still limited. The aims of this study were to evaluate the long-term efficiency of ADV add-on treatment based on virological response (VR), hepatitis B e antigen (HBeAg) clearance and alanine aminotransferase (ALT) normalization, and to explore the predictive factors associated with ADV add-on treatment.

METHODS

Patients

A TOTAL OF 158 patients (109 males and 49 females) were included in this retrospective study from 21 medical centers of the National Hospital Organization (NHO) in Japan. Both HBeAg positive and negative CHB patients were considered eligible if they had documented LAM resistance confirmed by detection of mutations in the YMDD motif of the reverse transcriptase gene of the virus (genotypic resistance), elevated serum HBV DNA levels (≥ 4 log copies/mL and/or >1 log copies/mL elevation from the LAM on-treatment nadir) and/or elevated serum ALT levels (>40 IU/L). Patients were excluded if they had decompensated liver cirrhosis, HCC at the initiation of ADV, or if they had co-infections (human immunodeficiency virus, hepatitis C virus) or other concomitant liver diseases such as autoimmune liver disease. Patients with no available clinical, biochemical, serological or virological data at baseline as well as every 6 months during treatment were also excluded.

Patient records were extracted from each institutional database. All data were labeled with their respective

institution and pooled. In total, 20 variables were examined to evaluate the long-term responses. The following variables were used as baseline factors: sex, HBeAg status, liver disease, age, body mass index, duration of LAM monotherapy, history of interferon (IFN) therapy, serum HBV DNA level, aspartate aminotransferase (AST), ALT, γ -glutamyl transpeptidase (γ -GTP), platelet (PLT) counts, and total bilirubin (T-Bil), albumin (Alb), prothrombin time (PT) and α -fetoprotein (AFP) levels. All were measured at the initiation of ADV therapy. For each variable, it was not used in the stepwise analysis if missing data accounted for more than 10% of the cases.

The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients and approval of this study was obtained from the NHO.

Statistical analysis

Three types of events were considered as outcomes: (i) VR; (ii) HBeAg clearance; and (iii) ALT normalization. VR was defined as serum HBV DNA levels of less than 3 log copies/mL by a quantitative real-time polymerase chain reaction assay, and ALT normalization was defined as a decrease in ALT levels to less than 31 IU/L during the on-treatment follow-up period. Baseline factors that could have an impact in the prediction of VR, HBeAg clearance as well as ALT normalization were investigated. The predictive value of several baseline parameters for VR was evaluated using time-to-event methods, because of the varying length of follow up. Time-to-event analysis was carried out using Kaplan-Meier estimates to draw cumulative incidence curves, compared by log-rank tests, as well as using univariate and multivariate Cox's proportional hazards models in combination with stepwise regression analysis. Factors contributing to HBeAg clearance and ALT normalization during ADV add-on therapy were estimated using multivariate multiple logistic regression analysis in combination with stepwise regression analysis. A stepwise variable selection procedure was used for variables that were at least marginally associated with the outcomes.

Covariates included in these analyses were binomial or continuous variables. Quartile analysis was initially performed separately for each continuous variable to make the decision regarding cut-off points. At first, we divided each continuous data into quarters to convert numerical values into four categorical values. Then, we estimated whether there was a regular trend among these four ordinal categorical data with outcome and selected a cut-off point among the 25th, 50th and 75th percentiles so that these variables could be appropriately

Table 1 Baseline characteristics at the initiation of add-on ADV therapy in LAM-resistant CHB patients based on HBeAg status

Baseline characteristics	HBeAg positive <i>n</i> = 99	HBeAg negative <i>n</i> = 59
Age (years)	51.6 (25.5–80.4)	59.3 (33.3–76.9)
Sex (male/female)	73/26	36/23
Liver disease (CH/cirrhosis)	79/20	38/21
Duration of LAM therapy (months)	29.8 (6.0–82.4)	39.3 (8.4–91.2)
History of IFN therapy (months)	39	15
HBV DNA (log copies/mL)	7.5 (2.1–7.6)	5.9 (2.1–7.6)
≤6	15	31
6–7.5	38	21
>7.5	46	7
Total bilirubin (mg/dL)	0.8 (0.3–5.2)	0.9 (0.41–3.7)
AST (IU/L)	60 (18–959)	60 (17–464)
ALT (IU/L)	80 (11–697)	86 (17–724)
γ-GTP (IU/L)	38 (12–325)	53 (10–740)
Albumin (g/dL)	4.3 (2.6–5.4)	4.3 (2.7–5.2)
Platelet count ($\times 10^4/\text{mm}^3$)	15.5 (3.7–50.0)	12.3 (1.7–33.2)

Continuous variables are expressed in median (range) and categorized variables in number.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CH, chronic hepatitis; γ-GTP, γ-glutamyl transpeptidase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM, lamivudine.

dichotomized. The hazards ratio (HR) and the odds ratio (OR) are presented with 95% confidence intervals (CI) and *P*-values, with less than 0.05 being considered statistically significant. All data analyses were processed using the R statistical software ver. 2.13.

RESULTS

IN THIS RETROSPECTIVE nationwide analysis of add-on ADV therapy in Japan, a total of 158 patients were enrolled from 2003–2010, consisting of 99 HBeAg positive and 59 HBeAg negative patients. Table 1 summarizes the baseline characteristics of the study popula-

tion; most were HBV genotype C. At the time of this analysis, the median total duration of ADV treatment was 41 months (range, 6–84), and the median time of LAM monotherapy, prior to initiation of ADV, was 34 months (range, 6–91).

VR

Figure 1 shows a Kaplan–Meier curve displaying the cumulative probability of VR based on HBV DNA levels among HBeAg positive and negative patients. Patients with a lower HBV DNA level displayed earlier VR than those with a higher HBV DNA level among both HBeAg positive and negative patients ($P < 0.001$, $P = 0.002$,




Figure 1 Cumulative rate of virological response on treatment with lamivudine plus adefovir dipivoxil depending on hepatitis B virus (HBV) DNA load in HBeAg positive and negative patients. hepatitis B e antigen (HBeAg) negativity and low HBV replication had a higher probability of virological response compared with HBeAg positivity or higher HBV replication. —, ≤6.0; ---, 6.1–7.5; ---, ≥7.6.

Table 2 Univariate and multivariate Cox's regression analysis of predictors of virological response

Variable	HBeAg positive n = 99				HBeAg negative n = 59	
	Univariate		Multivariate		Univariate	
	HR	P-value	HR	P-value	HR	P-value
Age (years) (<45/45≤)	0.91	0.69			0.66	0.34
Sex (male/female)	1.07	0.86			0.71	0.21
Liver disease (CH/cirrhosis)	0.61	0.069			1	0.99
Duration of LAM therapy (months) (<34/34≤)	0.92	0.76			1.72	0.076
History of IFN therapy (-/+)	0.83	0.43			0.89	0.73
HBV DNA (log copies/mL) (<7.0/7.0≤)	0.28	<0.001	<0.001	<0.001	0.44	0.012
Total bilirubin (mg/dL) (<1.0/1.0≤)	1.66	0.067	1.73	0.06	1.54	0.13
AST (IU/L) (<100/100≤)	1.57	0.061			1.11	0.71
ALT (IU/L) (<130/130≤)	1.51	0.085			1.05	0.87
γ-GTP (IU/L) (<70/70≤)	1.53	0.113			1.33	0.3
Albumin (g/dL) (<4.1/4.1≤)	0.51	0.011	0.48	0.0065	1.41	0.32
Platelet count (×10 ⁴ /mm ³) (<15/15≤)	0.93	0.77			1.1	0.74

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CH, chronic hepatitis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HR, hazard ratio; IFN, interferon; γ-GTP, γ-glutamyl transpeptidase; LAM, lamivudine.

respectively; log-rank test). HBeAg negative patients displayed higher VR rates than HBeAg positive patients at month 12 (89.9% vs 45.5%), month 24 (95.0% vs 61.5%), month 36 (98.4% vs 79.6%) and month 48 (98.4% vs 86.4%) of treatment. Even at a higher HBV DNA level (HBV DNA ≥ 7.0 log copies/mL), HBeAg negative patients displayed more rapid VR than HBeAg positive patients ($P < 0.001$). Seven patients did not achieve VR during the 4-year treatment, and one HBeAg positive patient developed ADV-resistant mutations without VR at month 44 of treatment. According to the results of the univariate Cox regression model, HBV DNA level and Alb level were associated with VR in HBeAg positive patients, while only the HBV DNA level was in HBeAg negative patients (HR = 0.44, 95% CI = 0.24–0.84, $P = 0.012$). In multivariate analysis, both lower HBV DNA level and lower Alb level were independent predictive factors associated with VR in HBeAg positive patients (HR = 0.26, 0.48, 95% CI = 0.15–0.44, 0.28–0.81, $P < 0.001$, $P = 0.0065$, respectively) (Table 2), while only the HBV DNA level was selected by a stepwise analysis for HBeAg negative patients.

HBeAg clearance or HBeAg seroconversion

Among 99 HBeAg positive patients, HBeAg clearance and seroconversion were achieved by 17.1% and 11.0% at month 24, by 24.3% and 14.3% at month 36 of treatment, and by 34.0% and 16.0% by the end of follow up, respectively. Except for a history of IFN

therapy (OR = 2.46, 95% CI = 0.94–6.6, $P = 0.047$), none of the other baseline variables were significantly associated with HBeAg clearance, according to the results of the univariate logistic regression analysis. In multivariate analysis, serum ALT level and history of IFN therapy were independent predictive factors for HBeAg clearance (Table 3). No patient experienced a reappearance of HBeAg or reverse seroconversion to HBeAg positive status during this treatment.

Normalization of ALT levels

The mean ALT level declined from 138.2 to 24.7 IU/L by add-on ADV therapy. Furthermore, addition of ADV to LAM-resistant CHB led to normalization of ALT levels in 75.2%, 79.5% and 82.7% of the patients at months 24 and 36, and at the final follow up, respectively. We next estimated the predictive factors for ALT normalization. Univariate logistic regression analysis revealed that only the baseline Alb level was significantly related to the ALT normalization. In the multivariate model, female patients (OR = 0.19, $P = 0.037$) and lower Alb level (OR = 0.19, $P = 0.0017$) were found to be independent predictors of ALT normalization.

DISCUSSION

ADD-ON ADV therapy has been a standard rescue treatment for patients with LAM-resistant HBV, but the overall benefits of long-term add-on ADV therapy

Table 3 Univariate and multivariate logistic regression analysis of predictors of HBeAg clearance and ALT normalization

Variable	HBeAg loss, <i>n</i> = 99				ALT normalization			
	Univariate		Multivariate		Univariate		Multivariate	
	Odds ratio	<i>P</i> -value	Odds ratio	<i>P</i> -value	Odds ratio	<i>P</i> -value	Odds ratio	<i>P</i> -value
Age (years) (<45/45≤)	0.42	0.065			0.94	0.85		
Sex (male/female)	3.02	0.075	2.99	0.081	0.4	0.34	0.19	0.037
Liver disease (CH/cirrhosis)	0.76	0.59			0.54	0.73		
Duration of LAM therapy (months) (<34/34≤)	1.1	0.97			0.59	0.39		
History of IFN therapy (-/+)	2.46	0.047	2.67	0.041	1.2	0.78		
HBV DNA (log copies/mL) (<7.0/7.0≤)	0.49	0.15			0.32	0.21		
Total bilirubin (mg/dL) (<1.0/1.0≤)	1.03	0.83			1.83	0.72		
AST (IU/L) (<100/100≤)	1.52	0.47			3.99	0.075		
ALT (IU/L) (<130/130≤)	2.44	0.061	2.74	0.043	3.71	0.13		
γ-GTP (IU/L) (<70/70≤)	2.16	0.17			1.29	0.98		
Albumin (g/dL) (<4.4/4.4≤)	0.9	0.99			0.17	0.0047	0.19	0.0017
Platelet count (×10 ⁴ /mm ³) (<15/15≤)	1.21	0.82			0.52	0.39		

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CH, chronic hepatitis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HR, hazard ratio; IFN, interferon; γ-GTP, γ-glutamyl transpeptidase; LAM, lamivudine.

have not yet been fully assessed. In this multicenter study of 158 patients from 21 hospitals over a mean follow-up period of 43.5 months, we tried to evaluate the long-term efficacy of add-on ADV therapy to LAM-resistant patients, and also to investigate which baseline factors were associated with VR, HBeAg clearance and ALT normalization. We found long-term add-on ADV treatment produced long-term virological and biochemical improvement. In addition, each outcome had different predictive factors; baseline HBV DNA and Alb level were predictive factors for VR in HBeAg positive patients, history of IFN therapy and ALT level for HBeAg clearance, and sex and Alb level for ALT normalization.

The rate of VR was 90.8% at 4 years of treatment. The strongest predictive factor for VR in both HBeAg positive and negative patients were confirmed by previous observations showing that add-on ADV therapy achieves more rapid and higher rates of VR when ADV is initiated in LAM-resistant patients with low viral replication levels.^{11–17} We also found that lower Alb level was an independent predictive factor for VR in HBeAg positive patients. In fact, baseline Alb correlated with PLT counts ($r = 0.51$, $P < 0.001$) and T-Bil ($r = -0.38$, $P < 0.001$), indicating that a lower Alb level reflected progression of liver disease. Little attention has been given to the relation of Alb level with VR – further studies will be needed to confirm our findings and understand its underlying mechanisms – but progression of chronic hepatitis might be predictive of VR under the add-on ADV treat-

ment. This is the first report to show the significance of baseline Alb levels as we used a time-to-event method for large populations, which is a more powerful and informative method to assess the association of factors to time-to-event outcomes.

The rate of HBeAg clearance was 34% at the end of follow up, which was compatible with previous observations.^{10,18} According to the results of multivariate analysis, IFN history was the strongest predictor of HBeAg clearance. Of the 37 patients, 17 (46%) who had previously received IFN therapy achieved HBeAg loss, suggesting that previous IFN therapy might have some immune modulatory effect on the ongoing combination therapy. IFN-induced HBeAg loss has been reported to be durable after a follow-up period of 4–8 years.^{19–21} In addition, baseline ALT levels were also significantly associated with HBeAg clearance in this study. Our results agree with those of many clinical studies that have shown baseline ALT levels to be the strongest predictor of HBeAg seroconversion in response to IFN therapy²² as well as nucleos(t)ide analog therapy.^{23,24}

Alanine aminotransferase normalization was achieved in 82.7% of the patients. ALT normalization and VR were independent of each other. Actually, among 24 patients who did not achieve ALT normalization, only seven had not achieved VR, suggesting that ALT elevation after sustained suppression of HBV replication might be associated with some conditions other than CHB. In addition, lower baseline Alb was revealed

to be an independent and positive predictive factor for ALT normalization. Considering that patients who did achieve ALT normalization had lower Alb levels than patients with elevated ALT at the final follow up (4.4 vs 4.6 g/dL, $P < 0.01$), and Alb levels are significantly higher in non-alcoholic fatty liver disease,²⁵ we speculate that fatty liver disease is related to the abnormal ALT. To clarify this, further studies by liver biopsy and/or ultrasonography will be needed.

In conclusion, long-term ADV treatment was highly effective in LAM-resistant CHB patients in terms of virological and biochemical response. In addition, the emergence of resistance to the add-on ADV therapy appears to be delayed and infrequent, in contrast to LAM. Furthermore, lower HBV DNA level and lower Alb level were significant predictive factors for better outcomes. Even though add-on ADV therapy in LAM-resistant CHB patients was highly effective in the long term, CHB patients with LAM or entecavir monotherapy need to be carefully followed-up and the optimal timing of ADV intervention should be determined on the basis of HBV DNA level and progression of liver disease.

ACKNOWLEDGMENTS

THIS STUDY WAS supported in part by a Grant-in-Aid from the NHO (no. H21-NHO(Kan)-01). We express our deepest appreciation to the members of the Liver Disease Network Group of the NHO and to their institutions. For complete details, please see Appendix I.

REFERENCES

- Lok ASF. Chronic hepatitis B. *N Engl J Med* 2002; 346: 1682–3.
- Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; 130: 678–86.
- Chen C-J, Yang H-I, Su J *et al.* Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; 295: 65–73.
- Conjeevaram HS, Lok AS-F. Management of chronic hepatitis B. *J Hepatol* 2003; 38 (Suppl 1): S90–103.
- Lai CL, Chien RN, Leung NW *et al.* A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; 339: 61–8.
- Lai C-L, Dienstag J, Schiff E *et al.* Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. *Clin Infect Dis* 2003; 36: 687–96.
- Lok ASF, Lai C-L, Leung N *et al.* Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; 125: 1714–22.
- Dienstag JL, Schiff ER, Wright TL *et al.* Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999; 341: 1256–63.
- Perrillo R, Hann H-W, Mutimer D *et al.* Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. *Gastroenterology* 2004; 126: 81–90.
- Peters MG, Hann Hw H, Martin P *et al.* Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. *Gastroenterology* 2004; 126: 91–101.
- Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. *Hepatology* 2005; 42: 1414–19.
- Papatheodoridis GV, Dimou E, Dimakopoulos K *et al.* Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. *Hepatology* 2005; 42: 121–9.
- Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. *Hepatology* 2007; 45: 307–13.
- Kurashige N, Hiramatsu N, Ohkawa K *et al.* Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. *J Gastroenterol* 2009; 44: 601–7.
- Shin SR, Koh KC, Gwak G-Y *et al.* A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. *Gut Liver* 2010; 4: 530–6.
- Mitsui F, Tsuge M, Kimura T *et al.* Importance of serum concentration of adefovir for Lamivudine-adevovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. *Antimicrob Agents Chemother* 2010; 54: 3205–11.
- Aizawa M, Tsubota A, Fujise K *et al.* Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. *J Med Virol* 2011; 83: 953–61.
- Buti M, Elefsiniotis I, Jardi R *et al.* Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. *J Hepatol* 2007; 47: 366–72.
- Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. *Gastroenterology* 1993; 105: 1833–8.
- van Zonneveld M, Honkoop P, Hansen BE *et al.* Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004; 39: 804–10.
- Niederer C, Heintges T, Lange S *et al.* Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996; 334: 1422–7.

- 22 Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. *Lancet* 1988; 2: 298–302.
- 23 Perrillo RP, Lai C-L, Liaw Y-F *et al.* Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. *Hepatology* 2002; 36: 186–94.
- 24 Schalm SW, Heathcote J, Cianciara J *et al.* Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. *Gut* 2000; 46: 562–8.
- 25 Jimba S, Nakagami T, Takahashi M *et al.* Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. *Diabetic Med* 2005; 22: 1141–5.

SUPPORTING INFORMATION

ADDITIONAL SUPPORTING INFORMATION may be found in the online version of this article:

Appendix S1 Relationship of liver cirrhosis with virological response on the basis of fibrosis, using 60 out of 158 patients liver biopsy had been performed. Fibrosis was related with platelet counts but neither with albumin levels nor with the virological response.

APPENDIX I

THE LIVER DISEASE Network Group of the National Hospital Organization consists of the following physicians and their institutions: Hiromi Ishibashi, Hiroshi Yatsuhashi, Department of Clinical Research Center, Nagasaki Medical Center; Makoto Nakamura, Department of Gastroenterology, Kyushu Medical Center; Michiyasu Yagura, Department of Gastroenterology, Tokyo National Hospital; Hirotsugu Takano, Department of Gastroenterology, Kure Medical Center; Takeaki Satoh, Center for Liver

Disease, Kokura Medical Center; Toyokichi Muro, Department of Gastroenterology, Oita Medical Center; Hideo Nishimura, Department of Gastroenterology, Asahikawa Medical Center; Hiroshi Mano, Department of Gastroenterology, Sendai Medical Center; Fujio Makita, Department of Gastroenterology, Nishigunma National Hospital; Akira Saitou, Department of Gastroenterology, Nishisaitama-chuo National Hospital; Masahiko Takahashi, Department of Gastroenterology, Tokyo Medical Center; Shigeo Hayashi, Department of Gastroenterology, National Disaster Medical Center; Tatsuji Komatsu, Department of Gastroenterology, Yokohama Medical Center; Yukio Watanabe, Department of Gastroenterology, Sagami National Hospital; Masakazu Kobayashi, Department of Gastroenterology, Matsumoto Medical Center; Hideo Morimoto, Hajime Ohta, Department of Gastroenterology, Kanazawa Medical Center; Masaaki Shimada, Department of Gastroenterology, Nagoya Medical Center; Toshiki Komeda, Department of Gastroenterology, Kyoto Medical Center; Taizo Hijioka, Department of Gastroenterology, Osaka Minami Medical Center; Haruhiro Yamashita, Department of Gastroenterology, Okayama Medical Center; Eiichi Takesaki, Department of Gastroenterology, Higashi Hiroshima Medical Center; Toru Hayashi, Department of Gastroenterology, Zentsuji National Hospital; Mitsuaki Koga, Department of Gastroenterology, Ureshino Medical Center; Kazuhiro Sugi, Department of Gastroenterology, Kumamoto Medical Center; Hironori Sakai, Department of Gastroenterology, Beppu Medical Center; Tetsuo Yamamoto, Department of Gastroenterology, Yonago Medical Center; Yukio Oohara, Department of Gastroenterology, Hokkaido Medical Center; Michio Kato, Department of Hepatology, Minamiwakayama Medical Center; Naohiko Masaki, Department of Gastroenterology, Kohnodai Hospital.